Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRInali-3 + Bevacizumab in 2L Advanced CRC
NCT07047560Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in colorectal cancer (CRC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Sep 2024; status: recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07047560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047560.